Robert Bradway

Robert Bradway has served as CEO of Amgen since 2012 and Chairman since 2013, making him one of the longest-tenured leaders in the biotechnology industry. He joined Amgen in 2006 from Morgan Stanley, where he led the healthcare investment banking practice. His financial background has shaped Amgen's strategy: disciplined capital allocation, aggressive share buybacks, and transformative M&A. Bradway's most significant deal was the $28 billion acquisition of Horizon Therapeutics in 2023, Amgen's largest ever, which added rare disease assets including Tepezza (thyroid eye disease) and Krystexxa (gout). The acquisition was nearly blocked by the FTC in an unusual challenge to a pharma deal without direct product overlaps, but Amgen prevailed, signaling regulatory limits on antitrust enforcement in biotech. The most consequential bet of Bradway's tenure may be MariTide, Amgen's obesity drug candidate. The GLP-1/obesity market — dominated by Eli Lilly's Mounjaro/Zepbound and Novo Nordisk's Ozempic/Wegovy — is projected to exceed $100 billion annually. MariTide's differentiated mechanism (a bispecific antibody requiring monthly dosing versus weekly injections) could carve a significant niche, but Phase 2 data in late 2024 showed modest weight loss, raising questions about competitiveness. Amgen's legacy franchise faces its own challenges: biosimilar competition is eroding sales of older blockbusters, and the company's growth increasingly depends on newer products like Tezspire (asthma) and Lumakras (cancer). Bradway must balance the massive R&D investment in obesity against maintaining the existing portfolio — all while managing $60+ billion in debt from the Horizon deal.